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Background. To examine factors contributing to extraocular muscle (EOM) volume enlargement in patients with Graves’ hyper-
thyroidism. Methods. EOM volumes were measured with orbital magnetic resonance imaging (MRI) in 39 patients with recently
diagnosedGraves’disease,andcomparedtoEOMvolumesof13normalvolunteers.Thyroidfunctiontests,uptakeonthyroidscin-
tigraphy, anti-TSH-receptor antibody positivity and other parameters were then evaluated in patients with EOM enlargement.
Results. 31/39 patients had one or more enlarged EOM, of whom only 2 patients had clinical EOM dysfunction. Compared to
Graves’diseasepatientswithnormalEOMvolumes,thosewithEOMenlargementhadsigniﬁcantlyhighermeanserumTSH(0.020
± 0.005 versus 0.007 ± 0.002 mIU/L; P value 0.012), free-T4 (52.9 ± 3.3v e r s u s4 1 .2 ± 1.7pmol/L; P value 0.003) and technetium
uptake on thyroid scintigraphy (13.51 ± 1.7% versus 8.55 ± 1.6%; P value 0.045). There were no diﬀerences between the 2 groups
in anti-TSH-receptor antibody positivity, the proportion of males, tobacco smokers, or those with active ophthalmopathy. Con-
clusions. Patients with recently diagnosed Graves’ disease and EOM volume enlargement have higher serum TSH and more severe
hyperthyroidism than patients with normal EOM volumes, with no diﬀerence in anti-TSH-receptor antibody positivity between
the two groups.
1.Introduction
Thyroid-associated ophthalmopathy (TAO) is an autoim-
munedisorderofuncertainaetiology.Whiletheinvolvement
of extraocular muscles (EOMs) in patients with Graves’ dis-
ease may seem infrequent on clinical examination, orbital
magnetic resonance imaging (MRI) studies suggest that the
majority of such patients have EOM enlargement [1].
Along with the orbital ﬁbroblast, the EOM is likely to be
a primary target in TAO. This is supported by evidence of T-
cell reactivity against both orbital ﬁbroblast and EOM cells
in vitro [2] and muscle ﬁbre damage in electron microscopic
studies of EOM from patients with recent onset TAO [3, 4].
In addition, expression of the thyrotropin-receptor (TSH-R)
in EOM [5, 6], as opposed to the widespread distribution of
TSH-R in adipose tissues throughout the body [7], may indi-
cate that EOMs have a more direct and speciﬁc role in TAO
than previously thought [8].
In this study, we investigated potential factors aﬀecting
EOMvolumeenlargementasmeasuredbyorbitalMRIinpa-
tients with recently diagnosed Graves’ disease.
2.MaterialsandMethods
A total of 39 patients diagnosed with Graves’ hyperthyroid-
ism within the preceding 3 months were selected for this
study. The patients were involved in a larger study looking
at potential risk factors for TAO [9].
The diagnosis of Graves’ disease was based on the pres-
ence of biochemical hyperthyroidism, a symmetrical goitre
and positive thyroid autoantibodies, and/or diﬀuse uptake
on 99mTechnetium thyroid nuclear scan. The abbreviated
clinical activity score (CAS) model wasemployed for the dia-
gnosis of active ophthalmopathy. This model assigns one
point for each of the following: spontaneous retrobulbar2 Journal of Thyroid Research
pain, pain on eye movement, eyelid erythema, eyelid oe-
dema, chemosis, conjunctival injection, and swelling of the
caruncle [10]. A total score ≥4 out of 7 was deﬁned as active
ophthalmopathy [11]. EOM function was evaluated by ask-
ing the patient to move their eyes in an H-shaped pattern,
andproptosiswasassessedusingaHertelexophthalmometer.
The ophthalmic examination was performed by a trained
clinical nurse.
Patients who were pregnant, less than 18 years of age,
andthosewithahistoryofradioactiveiodinetherapy,orbital
surgery, orbital irradiation, or signiﬁcant loss of vision were
excluded. The study was conducted at an outpatient endo-
crine practice in Victoria, Australia. Written, informed con-
sent was obtained, and the study was approved by the Bar-
won Health Research and Ethics Advisory Committee.
EOM volumes were measured by a single investigator
(SEK) from T1-weighted, 2mm slice orbital MRI scans using
the digital software MRIcro (Version 1.38 Beta; Chris Ror-
den) as previously described [9]. Brieﬂy, the volumes of the
medial, inferior, and lateral recti were measured manually
by circling the muscle perimeter on each slice. The superior
rectus muscle, the superior ophthalmic vein, and the levator
palpebrae superioris were measured together as the superior
muscle group (SMG) because of diﬃculties in delineating
these structures from each other. Orbital measurements were
expressed as a percentage of the mean globe volume for each
patient in order to adjust for interindividual variation in
EOM volumes.
3.StatisticalAnalysis
Statistical analysis was performed with the software pro-
grams Minitab 14.12 and SPSS 13.0. Proportions were com-
pared with Fisher’s exact test while the sample means were
evaluated with the 2-sample t-test. The eﬀect of TSH-R anti-
body positivity on EOM volume was examined with binary
logistic regression. Signiﬁcance was set at P value less than
0.05.
The cutoﬀ values of MRI-measured EOM volumes were
determined with receiver-operating-characteristic analysis
by comparing patient EOM volumes to those of 13 normal
volunteers with no history of thyroid or eye disease. The cut-
oﬀ values, their sensitivities and speciﬁcities, and the coeﬃ-
cients of variation of each measurement were detailed in an
earlier publication [9].
4. Results
Based on the EOM volume cutoﬀ value, only 8 patients had
normal volumes in all 4 EOM groups. Of the 31/39 patients
with at least one enlarged EOM volume, 3 patients had one
enlarged EOM, 3 patients had 2 enlarged EOM, 7 patients
had 3 enlarged EOM, and all 4 muscles were enlarged in 18
patients.ThemostfrequentlyaﬀectedEOMswerethemedial
and lateral (n = 27 each) followed by the inferior recti and
SMG (n = 24 each).
Assessment of baseline characteristics in patients with
and without EOM volume enlargement on MRI showed no
signiﬁcant diﬀerences in the proportion of males, tobacco
smokers, those with active ophthalmopathy (CAS ≥ 4), or
elevations in anti-TSH-R, antithyroid peroxidase (TPO), or
antithyroglobulin autoantibodies (Table 1). Only two pa-
tients, both with EOM volume enlargement, had clinically
evident EOM dysfunction.
However, patients with enlarged EOM volumes had sig-
niﬁcantly higher 99mtechnetium uptake on thyroid scintigra-
phy and greater serum free-T4 and thyrotropin (TSH) levels
(Table 2). Importantly, there were no signiﬁcant diﬀerences
between the two groups in the proportion of patients who
received anti-thyroid medications prior to recruitment into
the study. Overall, 8/31 patients with enlarged and 2/8 pa-
tientswithnormalEOMvolumesreceivedanti-thyroidmed-
ications for a mean 1.06 ±0.45 weeks and 1.13 ±0.79 weeks,
respectively. Exclusion of those patients from the analysis
resulted in persistent elevations of free-T4 and TSH levels in
patients with EOM enlargement, although the diﬀerences in
mean TSH became of borderline signiﬁcance (mean free-T4
42.4±1.9versus52.3±3.9pmol/L(P value0.034);meanTSH
0.021 ±0.006 versus 0.008 ±0.003mIU/L (P value 0.054)).
In further analysis using binary logistic regression, EOM
volumes were not associated with elevated anti-TSH-R, anti-
TPO, or antithyroglobulin autoantibodies, smoking, or the
presence of active ophthalmopathy.
5. Discussion
This study shows that patients with newly diagnosed Graves’
disease and EOM enlargement have higher serum TSH and
more severe hyperthyroidism, as suggested by the higher ser-
um free-T4 and greater uptake on thyroid scintigraphy, than
patients without EOM enlargement.
While more severe hyperthyroidism has not been identi-
ﬁed as an independent risk factor for TAO [12] ,agr e a t e rs e r -
um free-T3 at baseline is associated with an increased risk of
TAO after radioiodine therapy for Graves’ hyperthyroidism
[13]. In this study, EOM volume enlargement was associated
withhigherfree-T4levels(P value0.003;Table 2)andgr eater
uptake on thyroid scintigraphy (P value 0.045; Table 2). The
serumfree-T3levelwasgreaterinpatientswithEOMvolume
enlargementwithoutreachingstatisticalsigniﬁcance(P value
0.062; Table 2), perhaps due to the small sample size. The
mechanism whereby more severe hyperthyroidism leads to
greater EOM volumes is uncertain, but we speculate that it
may be related to higher levels of the shared thyroid-orbital
antigen(s).
Inthisstudy,themeanserumTSHwassigniﬁcantlyhigh-
er in patients with EOM volume enlargement. The role of
serum TSH in the initiation and propagation of TAO is well
documented after RAI therapy [13–16], and empirical thy-
roid hormone replacement after RAI ablation, but before the
onset of biochemical hypothyroidism, has been shown to
reduce the incidence of TAO after RAI [17]. It is possible that
EOMs,whichexpressTSH-R[5,6],aresensitivetoseemingly
minor elevations in serum TSH in patients with Graves’ hy-
perthyroidism, leading to greater EOM volumes. The higher
TSH levels in patients with enlarged EOM volumes occurred
despite higher free-T4 and free-T3 levels in this group. While
the serum TSH usually changes in a reciprocal fashion toJournal of Thyroid Research 3
Table 1: Comparison between patients with and without EOM volume enlargement. The number of patients is shown, and the proportions
P value was calculated using Fisher’s exact test.
Enlarged EOM Normal EOM P value
volume (n = 31) volume (n = 8)
Males 3 1 1.0
Smokers 9 3 0.7
Active ophthalmopathy 15 3 0.7
Clinical EOM dysfunction 2 0 1.0
Elevated TSH-R antibodies 23 7 0.6
Elevated thyroglobulin antibodies 14 5 0.4
Elevated TPO antibodies 19 7 0.2
Table 2: Means ± SEM of measurements for patients with and without EOM volume enlargement. Where the measurement was not per-
formed on all patients, the number of patients is shown in square brackets. P values calculated using 2-sample t-test.
Enlarged EOM Normal EOM P value
volume (n = 31) volume (n = 8)
Age (yrs) 44 ±2.14 0 .5 ±4.10 . 5
99mTechnetium uptake (%) 13.51 ± 1.7, (n = 28) 8.55 ±1.6, (n = 6) 0.045
TSH (mIU/L) 0.020 ±0.005 0.007 ±0.002 0.012
Free-T4 (pmol/L) 52.9 ±3.34 1 .2 ±1.7 0.003
Free-T3 (pmol/L) 22.8 ±1.9, (n = 29) 18.3 ±1.3 0.062
CAS 2.97 ±0.53 3.25 ±1.20 . 8
Proptosis (mm) 17.46 ±0.46 16.00 ±0.71 0.097
the serum free-T4 and free-T3 levels, it is worth noting that
this relationship is attenuated or “ﬂattened” in hyperthyroid
patients with a suppressed serum TSH below 0.01mIU/L
[18].Uponstartingtreatmentwithanti-thyroidmedications,
the serum free-T4 and free-T3 fall rapidly whereas the serum
TSH typically “lags” behind and remains undetectable for up
to 3 months [18]. It is therefore unlikely that the greater ser-
umTSHinpatientswithEOMvolumeenlargementwasrela-
ted to treatment with anti-thyroid medications prior to re-
cruitment into the study, especially because the mean dura-
tion of treatment with anti-thyroid medications was 1.08 ±
0.39 weeks, and did not exceed 3 months in any patient. In
addition, exclusion of patients who received anti-thyroid
medications from the analysis did not abolish the diﬀerences
in serum TSH between the two groups, although the dif-
ferences became of borderline signiﬁcance (P value 0.054),
possibly due to the smaller sample size.
While the majority of patients in this study had elevated
anti-TSH-R antibody levels, there were no signiﬁcant diﬀer-
ences in the prevalence of anti-TSH-R antibody positivity
between patients with and without EOM volume enlarge-
ment, and in binary logistic regression analysis there was no
association between antibody positivity and EOM volumes.
TAO is thought to occur following sensitization of T-lym-
phocytestoacommonthyroidandorbitalantigen.Theiden-
tity and location of this antigen remains unknown, but the
TSH-R is the most likely candidate [7, 19]. Autoimmunity
againstotherantigensparticularlytheskeletalmuscleprotein
calsequestrin [20] is of potential importance, but is not well
understood.TheroleofTSH-Rintheinitiationandpropaga-
tion of TAO is supported by the close temporal relationship
between the onset of ophthalmopathy and Graves’ disease
which is caused by stimulating anti-TSH-R antibodies [12],
andthepositivecorrelationbetweentheseantibodiesandthe
prevalence of TAO in untreated Graves’ disease [21]. In addi-
tion, TSH-R antibody levels are closely associated with CAS
readings, the severity of the eye disease [22], and to a lesser
extent with proptosis [23]. Therefore, the lack of an associ-
ation between TSH-R antibody positivity and EOM volume
enlargementinthisstudyshouldbeinterpretedwithcaution,
especially because of the small sample size and the increased
risk of a type 2 error.
Similarly, the small sample size may account for non-
signiﬁcant diﬀerences in measures of proptosis, which was
greater in patients with enlarged EOM volumes without
reaching statistical signiﬁcance (P value 0.097; Table 2). In
contrast, the lack of an association between active ophthal-
mopathy and EOM enlargement may be related to the use
of the CAS model which measures soft tissue and periorbital
inﬂammation rather than EOM involvement [10, 24].
6. Conclusions
In patients with newly diagnosed Graves’ disease, EOM vol-
ume enlargement is associated with greater serum TSH levels
and more severe hyperthyroidism, as suggested by greater
serum free-T4 levels and more avid uptake on thyroid scin-
tigraphy. There was no association between EOM volumes
andanti-TSH-R antibody positivity, although the smallsam-
ple size may have contributed to this negative ﬁnding. Larger
studies are needed to examine the relationship between ser-
um TSH, anti-TSH-R antibodies, and EOM enlargement.4 Journal of Thyroid Research
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